Robert P. Lenk - 13 Aug 2025 Form 4 Insider Report for PLUS THERAPEUTICS, INC. (PSTV)

Reporting relationship: Director
Issuer ticker: PSTV
Reported as of: 13 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Aug 2025, 16:29:07 UTC
Prior SEC filing: 20 Feb 2025
Next SEC filing: 25 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Andrew Sims, attorney-in-fact

Key filing fact

Robert P. Lenk filed Form 4 for PLUS THERAPEUTICS, INC. (PSTV) on 15 Aug 2025.

Key facts

This page summarizes Robert P. Lenk's Form 4 filing for PLUS THERAPEUTICS, INC. (PSTV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Aug 2025, 16:29.

Change

Previous filing in this sequence was filed on 20 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001362635 Primary reporting owner

Lenk Robert P

Relationship: Director
Address: C/O PLUS THERAPEUTICS INC., 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN
Signature: /s/ Andrew Sims, attorney-in-fact
Signature date: 15 Aug 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PSTV transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +297,794
Change %
Price: $0.000000
Shares after: 297,794
Date: 13 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 297,794
Exercise price: $0.5744
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options vest monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the options vest in full on the Issuer's 2026 Annual Stockholder Meeting, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting.